We are developing FT-338, a next-generation oral ferroptosis inhibitor designed for full brain penetration to halt lipid peroxidation–driven neurodegeneration. Unlike first-generation compounds that failed due to poor CNS exposure, FT-338 shows 3× higher potency, excellent metabolic stability, and favorable safety in preclinical studies. The technology targets Friedreich’s Ataxia as an initial indication, with expansion potential across ALS, Parkinson’s, and Alzheimer’s disease.

Planned milestones (12–24 months):
(1) Complete in vitro efficacy studies vs. vatiquinone + Skyclarys;
(2) Demonstrate in vivo efficacy in FA mouse models;
(3) Advance to pre-IND readiness and initiate fundraising for IND-enabling studies.